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ABSTRACT
Objective: A series of novel synthesis of 5-Substituted-3-phenyl-4,5-dihydro-pyrazole-1-carbothioic acid [4-(9, 10-dihydro-acridin-9-yl)-phenyl]-
amide (IV) were synthesized using standard procedures and evaluated for cytotoxic studies.
Methods: 9-(4-Chloro-phenyl)-9 and 10-dihydro-acridine (I) were formed by cyclization of diphenylamine with substituted acids in the prescience 
of zinc chloride and synthesis of 5-substituted-3-phenyl-4, 5-dihydro-pyrazole-1-carbothioic acid amide (3) by the cyclization of different chalcones 
(II) and final compounds were synthesized by fusion of 5-substituted-3-phenyl-4, 5-dihydro-pyrazole-1-carbothioic acid amide (III) with 9-(4-Chloro-
phenyl)-9, 10-dihydro-acridine (I) by microwave irradiation method. Characterization of synthesized compounds by infrared, 1H nuclear magnetic 
resonance (NMR), 13C NMR, and mass spectroscopic methods. Obtained compounds were evaluated for their cytotoxicity against human breast cancer 
cell lines (MCF/wt) by sulforhodamine-B assay. Docking studies with Aurora kinase protein were performed to elucidate the possible mechanistic 
insights of these novel acridine tagged pyrazole derivatives.
Results: Moderate to good in vitro cytotoxic potentials of the newly synthesized molecules was reported against selected human breast cancer 
cell lines. Among the tested molecules, compound C6 showed good cytotoxic activity against MCF/wt (08.2±0.4 μM). The dock scores of the tested 
compounds were ranged between −8.926 and −5.139. Compound C6 which has been reported as the most effective cytotoxic agent among the series 
also reported the highest dock score of -8.926 and showed hydrogen bond interaction with GLU-211, LYS-162, and LYS-143. Ligand binding energy 
with protein suggested compound C6 has shown the highest binding energy of −86.32133 kcal/mol.
Conclusion: The in vitro studies of the newly synthesized acridine tagged pyrazole derivatives reported considerable cytotoxic potentials against 
human breast cancer cell lines and structure-activity relationship studies to suggest that acridine tagged pyrazole derivatives with hydroxy group 
present on phenyl ring at fifth position of pyrazole ring could probably increase the cytotoxic potentials. With the reported bioactivities of these 
derivatives, further studies on the derivatization could elucidate the broader cytotoxic potentials.
Keywords: Microwave irradiation, Acridine, Pyrazoles, Chalcones, Aurora kinase.
INTRODUCTION
Across the world, cancer is being considered as a major cause for 
elevated mortality rate in humans. Among women, breast cancer is 
the most prevalent cancers with an estimate of 255,180 new cases, 
respectively [1]. Elevated levels of Aurora kinases detected in wide 
variety of human cancers strongly indicate that high expression of 
these kinases plays an important role in the development of anticancer 
molecules as aurora kinase inhibitors [2].
Acridine (C13H9N) is a nitrogen heterocycle, which is structurally related 
to anthracene with one of the central CH groups replaced by nitrogen. The 
acridines were first developed as dyes and during the early 20th century 
their pharmacological properties were evaluated. At this time, proflavine 
was used as a topical antibacterial and antifungal agent [3]. In the 1940’s 
and to the present day, the acridines (e.g., quinacrine, pyronaridine, and 
acranil) have been used as antimalarial drugs [4]. The first acridine-
based therapeutic agents specifically designed for cancer treatment were 
developed during the 1970’s. These efforts led to the development of 
m-amsacrine, a 9-anilinoacridine introduced into clinical use in 1976 [5]. 
Accordingly, this acridine has been clinically utilized as a single agent or 
in combination with other anti-neoplastic drugs in the treatment of acute 
nonlymphocytic, lymphocytic [6,7] and acute myeloid [8], leukemias [9]. 
However, m-Amsacrine has not generally been effective in the treatment 
of solid tumors [10]. Acridine has an irritating odor. It crystallizes in 
colorless to light yellow needles with melting point of 110°C and boiling 
point of 346°C. It is characterized by its irritating action on skin and by 
the blue fluorescence showed by solutions of its salts.
Pyrazoles are five member ring heterocyclic compounds, have some 
structural features with two nitrogen atoms in adjacent position, and 
are also called as azoles [11].
β-[1-pyrazolyl] alanine was isolated from the seeds of water melons 
(Citrullus lanatus). The best described property of almost every group 
of pyrazoles is in the treatment of inflammation and inflammation 
associated disorders, such as arthritis [12]. Pyrazole derivatives are 
the subject of many research studies due to their widespread potential 
biological activities such as antimicrobial [13], antihistaminic [14], 
antidepressant [15], 5-α-reductase inhibitor [16], antiproliferative [17], 
and herbicides [18]. During the years, pyrazoles are proved to be potent 
Aurora kinase inhibitors (IC50 = 0.16±0.03 μM) [19].
METHODS
Chemistry
All the chemicals were obtained from Sigma-Aldrich chemical company 
(USA), Lancaster (USA) and S.D. Fine chem. Limited (Mumbai). All the 
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glassware is of borosilicate grade. Melting points were determined in 
open capillaries and are uncorrected. The purity of the compounds was 
ascertained by thin-layer chromatography (TLC) on silica gel-G plate.
Fourier transform infrared (IR) spectra were taken in KBr on a Thermo 
Nicolet Nexus 670 spectrophotometer. 1H nuclear magnetic resonance 
(NMR) spectra were recorded on AVANCE 300 MHz spectrophotometer in 
CDCl3 with tetramethylsilane (TMS) as internal standard. 13C NMR spectra 
were recorded on BRUKER AVANCE 300MHz spectrometer in CDCl3 with 
TMS as an internal standard. The chemical shift values are in δppm. Mass 
spectra were recorded on Polaris Q apparatus (Thermo Electron) and 
the fragmentations were obtained by electronic impact (EI). The data are 
given as mass to charge ratio (m/z) and nominal masses were used for 
the calculation of molecular weights of the prepared products.
Synthetic procedure
Step 1: General procedure for synthesis of 9-(4-chlorophenyl)-9, 
10-dihydroacridine (1)
A mixture of diphenylamine (0.01 mol) and 4-Chloro benzoic acid 
(0.01 mol) was taken in a conical flask. To this zinc chloride (0.01 mol) 
was added as solvent. Then, the reaction mixture was irradiated under 
microwave irradiation at 450 W for 11 min. The precipitate obtained 
after cooling is filtered and recrystallized with methanol.
Step 2: General procedure for synthesis of chalcones (II)
Equimolar quantity of different aldehydes (0.01 mol) and acetophenone 
(0.01 mol) (1.2 mL) was placed in 30 mL of ethanol. The mixture was allowed 
to stir for 15 min. A 10 mL 40% aqueous potassium hydroxide solution was 
slowly added dropwise to the reaction flask through a dropping funnel. The 
reaction solution was allowed to stir at room temperature for 1.5 h. The 
solid separates and was collected by suction filtration.
Step 3: General procedure for synthesis of 5-substituted-3-phenyl-4, 
5-dihydro-pyrazole-1-carbothioic acid amide (III)
A mixture of chalcones (II) (0.01 mol), thiosemicarbazide (0.01 mol, 
0.91 g), and KOH (0.0025 mol, 1.4 g) was refluxed in ethanol (30 mL) for 
6 h. The solution was poured into ice-water. The precipitate was filtered 
and recrystallized from methanol.
Step 4: General procedure for the synthesis of 5-substituted-3-phenyl-4, 
5-dihydro-pyrazole-1-carbothioic acid [4-(9, 10-dihydro-acridin-9-yl)-
phenyl]-amide (IV)
In a 250 ml flask, a mixture of (0.03 mol) of 5-substituted-3-phenyl-4, 
5-dihydro-pyrazole-1-carbothioic acid amide (III), (0.0256 mol) of 
9-(4-Chloro-phenyl)-9, 10-dihydro-acridine (1), and 80 ml of 2-butanol 
was taken and subjected to microwave irradiation for 3 min at 65% 
intensity (455 W). Completion of the reaction was monitored by TLC 
using n-hexane and ethyl acetate in 6:4 ratio. After completion, the 
reaction mixture was allowed to cool at room temperature then it was 
poured into 150 ml of ice water. A precipitate formed was filtered by 
suction, washed with water and dried recrystallized from ethanol.
The spectral data for all the newly synthesized compounds were 
completely in agreement with the proposed structures.
N-(4-(9,10-dihydroacridin-9-yl)phenyl)-5-phenoxy-3-phenyl-4,5-
dihydro-1H-pyrazole-1-carbothioamide (C1)
Light yellow color solid, yield-72%, m.p. 310–312°C, IR (KBr): 1597 cm−1 
(-NH-), 1487 cm-1 (C=S), and 1680 cm−1 (-OCH3), 1H NMR (CDCl3): δ ppm 
2.5 (s, 2H-CH2 protons), δ ppm 4.0 (s, 1H-NH proton), δ ppm 4.7 (s, CH), 
δ ppm 4.7 (s, 3H-OCH3protons). and δ ppm 6.9–8.0 (m, 21H- Aromatic 
protons), M.W-552.69 g/mol, EI-MS: m/z 554(M+1).
3, 5-Diphenyl-4, 5-dihydro-pyrazole-1-carbothioic acid [4-(9, 10-dihydro-
acridin-9-yl)-phenyl]-amide (C2)
White color solid, yield-63%, m.p. 323–325°C, IR (KBr): 1625 cm−1 
(-NH-) and 1494 cm−1 (C=S), 1H NMR (CDCl3): δ ppm: 2.1(s, 2H-CH2 
protons), 4.1 (s, 1H-NHprotons), 3.8 (s,1H-N-CH protons) 5.7 (s,1H-CH 
protons) and 7.2–8.0 (m, 22 H-Ar-H), M.W-536.69 g/mol, EI-MS: m/
z536(M). 13C NMR (100 MHz, CDCl3) δ ppm 117.92–143.24 represents 
30 aromatic carbons, δ ppm 156.09 represents C=N carbon, δ ppm 
43.23 represents Pyrazole CH2 carbon, δ ppm 63.08 represents pyrazole 
CH carbon, δ ppm 176.91 represents C=S carbon. M.W-536.69 g/mol, 
EI-MS: m/z 536(M).
3-Phenyl-5-styryl-4, 5-dihydro-pyrazole-1-carbothioic acid [4-(9, 
10-dihydro-acridin-9-yl)-phenyl]-amide (C3)
Light yellow color solid, yield-55% yield, m.p. 310–312°C, IR (KBr): 
1502 cm−1 (-NH-), 1400 cm−1 (C=S), and 1311 cm−1 (-CH=CH2), 1H NMR 
(CDCl3): δ ppm: 2.0 (s, 2H-CH2protons), 4.1 (s, 1H -NH protons), 3.2 
(s, 1H-CH protons), 5.4 (s,1H-CH protons) and 7.0–7.8 (m, 22H-Ar-H), 
M.W-562.73 g/mol, EI-MS: m/z 562 (M-1).
5-(4-Dimethylamino-phenyl)-3-phenyl-4, 5-dihydro-pyrazole-1-
carbothioic acid [4-(9, 10-dihydro-acridin-9-yl)-phenyl]-amide (C4)
Cream color solid, yield-58%, m.p. 307–310°C, IR (KBr): 1604 cm−1 
(-NH-), 1401 cm−1 (C=S), and 1022 cm−1 (-N(CH3)2, 1H NMR (CDCl3): 
δ ppm: 1.1 (s, 2H-CH2protons), 2.7 (s-6H-NCH3), 4.0 (s, 1H-NH protons), 
5.0 (s, 1H-CH protons) and 6.9–8.0 (m, 22H, Ar-H), M.W-579.76 g/mol, 
EI-MS: m/z 579 (M-1).
5-(4-Nitro-phenyl)-3-phenyl-4, 5-dihydro-pyrazole-1-carbothioic acid [4-
(9, 10-dihydro-acridin-9-yl)-phenyl]-amide (C5)
Yellow color solid, yield-52%, m.p. 314–317°C, IR(KBr): 1595 cm−1 (-NH-), 
1450 cm−1 (C=S), and 1575 cm−1 (-NO2), 1H NMR (CDCl3): δ ppm: 1.3 (s,2H-
-CH2protons), 4.0 (s,1H-NH protons), 3.4 (s, 1H-CH protons) and 6.8–7.8 
(m, 21H-Ar-H), M.W-581.69 g/mol, EI-MS: m/z 581 (M-1), 583 (M+1).
5-(4-Hydroxy-phenyl)-3-phenyl-4, 5-dihydro-pyrazole-1-carbothioic acid 
[4-(9, 10-dihydro-acridin-9-yl)-phenyl]-amide (C6)
White color solid, yield-70%, m.p. 327–330°C, IR (KBr): 1575 cm−1 
(-NH-), 1469 cm−1 (C=S), and 3520 cm−1 (-OH, Phenolic), 1H NMR 
(CDCl3): δ ppm: 2.1 (s, 2H-CH2 protons), 3.9 (s, 1H-NH protons), 3.2 
(s,1H-CH proton), 5.0 (s,1H-OH, Phenolic protons) and 7.3–7.9 (m, 21H, 
Ar-H) M.W-552.69 g/mol, EI-MS: m/z 553(M).
5-Methyl-3-phenyl-4, 5-dihydro-pyrazole-1-carbothioic acid [4-(9, 
10-dihydro-acridin-9-yl)-phenyl]-amide (C7)
Cream color solid, yield-72%, m.p. 295–297°C, IR (KBr): 1510 cm−1 
(-NH-), 1444 cm−1 (C=S), and 1461 cm−1 (-CH3), 1H NMR (CDCl3): δ ppm: 
2.1 (s, 2H,CH2 protons), 4.8 (s,1H-NH protons), 3.2 (s, 1H-CH proton), 
1.4 (s, 3H-CH3 protons) and 7.0–7.8 (m, 17H-Ar-H), M.W-474.62 g/mol, 
EI-MS: m/z 475(M).
3-Phenyl-5-propenyl-4, 5-dihydro-pyrazole-1-carbothioic acid [4-(9, 
10-dihydro-acridin-9-yl)-phenyl]-amide (C8)
White color solid, yield-59%, m.p. 300–302°C, IR (KBr): 1581 cm−1 
(-NH-), 1508 cm−1 (C=S), 1469 cm−1 (-CH3), and 1342 cm−1 (-CH=CH2), 
1H NMR (CDCl3):δ ppm: 2.0 (s, 2H-CH2 protons), 4.0 (s,-NH protons), 
3.2 (s, 1H-CH proton) 1.1 (s,3H-CH3 protons) 5.6 (s, 2H vinylic protons) 
and 7.3–7.8 (m, 17H-Ar-H), M.W-500.66 g/mol, EI-MS: m/z 500(M-1).
In vitro cytotoxic activity
In vitro cytotoxic studies of synthesized compounds of acridine tagged 
pyrazole derivatives compounds in comparison with reference drugs 
Doxorubicin (Dx) mitoxantrone (Mr) were studied by sulforhodamine-B 
(SRB) assay [20]. In brief, cells were cultured in RPMI 1640 supplemented 
with 10% fetal calf serum, and cultures were passaged once or twice a 
week using trypsin EDTA to detach the cells from their culture flasks. 
The fast-growing cells were harvested, counted, and plated at suitable 
concentrations in 96-well microplates. Cells were allowed to adhere for 
24 h. Thereafter, one plate was fixed to determine the initial absorbance 
(T0). To the other plates compounds dissolved in the culture medium 
were added to the culture wells in triplicate and incubated further for 
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72 h at 37°C under 5% CO2 atmosphere. The cultures were fixed with 
cold TCA and stained with 0.4% SRB dissolved in 1% acetic acid. After 
dissolving the bound stain with 150 uL of 10 mM unbuffered Tris-base 
(Tris(hydroxymethyl)aminomethane) solution using gyratory shaker, 
absorbance was measured at 540 nm using a microplate reader (Tecan). 
Growth was calculated by correcting the control plate (without drugs) 
cultured for 72 h (T72 control) with the T0 plate. Growth inhibition was 
calculated as: (T72 drug−T0)/(T72 control−T0)⁄100%. The efficacy of the 
compounds was compared by estimating the concentration required 
to inhibit cellular growth by 50% (i.e. IC50) from each separate growth 
inhibition curve. Each value represents the mean of triplicate experiments.
Molecular docking and binding energy calculations
Dataset ligands and ligand optimization cytotoxic activity possessing 
acridine tagged pyrazole derivatives which were earlier developed 
in our laboratory were selected (Scheme 1) [21]. 2D structures of 
the compounds were converted to 3D using potential algorithms and 
application of high efficient force fields. Initial geometrical optimization 
and energy minimization of molecules were performed using the 
LigPrep tool of Schrodinger suite [22]. Various ionization states were 
generated using LigPrep module using a special program EPIK along 
with various possible conformers and tautomers.
Molecular properties of the processed ligands were studied using 
Qikprop module. Qikprop module also predicts ADME profiles 
such as blockage of Human Ether-a-go-go-related Gene (hERG) K+ 
channels, apparent Caco-2 cell permeability, brain/blood partition 
coefficient, apparent Madin-Darby canine kidney cell permeability, 
skin permeability, binding to human serum albumin, and human oral 
absorption of the given set of ligands [23].
Scheme 1: Synthesis of acridine tagged pyrazole derivatives
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(Contd...)
Molecule R MW log P Yield (%) MP (°C)
C1 552.69 8.18 70 310–312
C2 536.69 8.3 63 323–325
 C3 562.73 8.82 55 310–312
C4 579.76 8.59 58 307–310
C5 589.61 7.99 52 314–317
C6 552.69 7.91 70 327–330
C7 474.62 6.91 72 295–297
C8 500.66 7.63 59 300–302
C9 571.13 8.86 69 280–283
C10 581.69 7.92 58 278–281
C11 526.65 6.92 72 261–263
C12 616 7.4 70 265–268
C13 616 7.92 69 263–265
Table 1: Physical characterization data of acridine tagged pyrazole derivatives
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Table 1: (Continued)
Molecule R MW log P Yield (%) MP (°C)
C14 581.69 7.65 63 252–255
C15 593.74 7.21 68 301–303
C16 594.72 7.89 71 283–285
C17 582.71 7.79 68 275–278
C18 630.60 8.33 69 286–289
C19 566.71 8.18 71 291–293
C20 645.61 9.01 65 310–312
C21 615.58 9.13 68 291–293
C22 587.13 8.47 60 287–289
C23 642.81 9.91 64 278–281
C24 550.72 8.79 72 282–286
C25 616.13 8.89 66 271–274
(Contd...)
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The digital structure of the Aurora-A kinase protein was retrieved from 
the protein databank website with PDB Id: 1MQ4 and the structure 
was optimized by deleting unbound water molecules which are over 
1 Å, adding hydrogen atoms to satisfy the valences, adding missing 
amino acids to stabilize side chains and energy of the whole structure 
was minimized using OPLS-2005 force field using Protein Preparation 
Wizard tool of Schrodinger Suite [24]. Thus, structurally optimized 
protein structure was used to examine protein-ligand interactions of 
the dataset ligands using Glide Xp docking protocol. Initially, a 3D grid 
was established to the binding pocket (active site) of the protein, into 
which all the dataset ligands were docked into. Binding interactions and 
efficiency of the binding were calculated in terms of Glide Score, which 
is a combination of hydrophilic, hydrophobic, metal binding groups, Van 
der Waals energy, freezing rotatable bonds, and polar interactions with 
receptor [25]. GScore = 0.065× Van der Waals energy+0.130× Coulomb 
energy+Lipophilic term (Hydrophobic interactions)+H bonding+Metal 
binding+BuryP (Penalty for buried polar groups)+RotB (Penalty for 
freezing rotatable bonds)+Site (Polar interactions in the active site) 
Post docking calculations Prime MM/GBSA (molecular mechanics 
based generalized Born/surface area), module of Schrodinger suite was 
used to calculate the binding energies of the docked complexes, which 
is a combination of OPLS molecular mechanics energies (EMM), an SGB 
solvation model for polar solvation (GSGB), and a non-polar solvation 
term (GNP) containing non-polar solvent accessible surface area and 
Van der Waals interactions. In this, docking results were rescored 
through an energy function with a well-defined description of binding 
contributions. The total free energy of binding is then expressed in the 
form below mentioned Equation [22]:
ΔGbind = Gcomplex – (Gprotein + Gligand)
Where, ΔGbind is ligand binding energy.
RESULTS
Chemistry
Acridine tagged pyrazole derivatives have been synthesized and 
the reaction sequence for the synthesis of compounds is outlined 
in Scheme 1. Physical Characterization data of newly synthesized 
compounds are outlined in Table 1. The protein ligand interactions and 
post docking calculations of acridine tagged pyrazole derivatives with 
aurora kinase are shown in Table 2. Cytotoxic activity of acridine tagged 
pyrazole derivatives is shown in Table 3.
Cytotoxic activity
All the synthesized compounds were evaluated for their cytotoxic 
activity against humanw breast cancer MCF/wt cell line by SRB assay 
using standard drug doxorubicin mitoxantrone.
For each cell line, the IC50 values (response parameter) were calculated 
and outlined in Table 2.
Table 2: Cytotoxic activity of acridine tagged pyrazole 
derivatives

















Molecule R MW log P Yield (%) MP (°C)
C26 578.77 9.54 69 267–269
C27 605.58 9.42 68 301–303
C28 580.74 8.51 71 288–301
C29 564.74 9.28 66 283–285
C30 566.71 8.18 69 305–308
Table 1: (Continued)
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binding energy with protein suggested that compound C6 has shown 
the highest binding energy of −86.32133 kcal/mol, protein-ligand 
interactions along with binding energies of acridine tagged pyrazole 
derivatives with aurora kinase are shown in Table 3.
The majority of interactions are observed with acridone N-atom with 
LEU 139. Substituted halogens also show substantial interactions.
Table 3: Protein ligand interactions and post docking calculations of acridine tagged pyrazole derivatives with aurora kinase
Compound Dock score No of H-bonds Interacting amino acids H-bond distance Bond energy



















c19 −6.617 1 LEU 139 2.66 −69.017
c18 −6.545 1 LEU 139 2.66 −69.696
c27 −6.418 1 LYS 258 2.74 −72.608
c16 −6.405 1 LEU 139 2.75 −74.62
c30 −6.36 0 - - −73.519
c23 −6.357 1 LEU 139 2.70 −77.467
c25 −6.344 1 LEU 139 2.32 −68.847
c17 −6.281 1 LEU 139 2.66 −72.458
c9 −6.266 0 - - −67.57
c4 −6.266 1 LEU 139 2.67 −70.836





c28 −6.216 0 - - −71.688
c26 −6.171 0 - - −65.321
c3 −6.154 0 - - −73.544
c22 −6.117 1 LEU 139 2.79 −67.504
c29 −6.112 0 - - −72.295
c13 −6.091 1 LEU 139 2.51 −64.779
c14 −6.077 0 - - −71.29





c1 −6.001 0 - - −64.898
c10 −5.996 1 TRP 277 1.91 −62.737










C7 −5.67 0 - - −64.912
c11 −5.669 1 LEU 139 2.50 −70.09
c8 −5.468 0 - - −61.574
c24 −5.139 1 LYS 258 2.25 −65.201
Molecular docking and binding energy calculations
The association of Aurora kinase in the human breast cancers was 
observed from the previous reports. The dock scores of the tested 
compounds were ranged between −8.926 and −5.139. Compound C6 
has been reported as the most effective cytotoxic agent among the series 
also reported the highest dock score of −8.926 and showed hydrogen 
bond interaction with GLU-211, LYS-162, and LYS-143 (Fig. 1). Ligand 
Fig. 1: Binding interactions of compound C6 at kinase domain of aurora kinase protein
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DISCUSSION
We have designed a convenient method for the synthesis of acridine 
tagged pyrazole derivatives and screened for in vitro cytotoxic activity 
against human breast cancer cell lines MCF/wt. By observing the above 
results, these synthesized compounds showed good cytotoxic activity 
of IC50 values in the range of 08.2±0.4–21.2±0.3. The electron releasing 
OH group in compound C6 is responsible for good binding interaction 
at kinase domain of aurora kinase protein.
CONCLUSION
In the present study, novel acridine tagged pyrazole derivatives were 
synthesized. The synthesized compounds were characterized by IR, 
1H NMR, 13C NMR, and mass spectrum. All the synthesized compounds 
showed characteristic absorption peaks in IR, 1H NMR, and mass 
spectrum. Synthesized compounds were evaluated for in vitro cytotoxic 
activity by SRB assay against human breast cancer cell lines MCF/wt.
The cytotoxic activity of the synthesized compounds revealed that the 
maximum activity was obtained when R was substituted by a hydroxyl 
group in the phenyl ring of pyrazole moiety. It was found that the 
compounds possessing electron releasing groups considerably enhance 
the cytotoxic activity when compared to the electron withdrawing 
groups on the phenyl ring.
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